Moderna will get up to $54.3 million in funding from a global coalition to support late-stage development of its experimental ...
The Coalition for Epidemic Preparedness Innovations said it will invest $54.3 million with Moderna to fund a Phase 3 trial of ...
Moderna announced Thursday it will receive up to $54.3 million from a global vaccine partnership to fund its ongoing research ...
Up to $54.3 million CEPI investment aims to help advance Moderna's H5 pandemic influenza vaccine candidate to licensure ...
NEXSPIKE is Moderna’s third product to receive a positive CHMP opinion alongside Spikevax (COVID-19 Vaccine, mRNA) and ...
As support from the U.S. government has evaporated, Moderna is leaning on an old ally to carry plans for its prospective mRNA ...
CAMBRIDGE, MA / ACCESS Newswire / December 17, 2025 / Moderna, Inc. (Nasdaq:MRNA) today announced it will present at the 44th annual J.P. Morgan Healthcare Conference on Monday, January 12th at 7:30 p ...
Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups ...
Since that moment, Moderna has taken steps to pave the path to long-term growth -- from cutting costs to focusing on its vast ...
The fresh capital provides another shot for Moderna's candidate against bird flu, which earlier this year lost its government ...
Moderna (MRNA) stock is in focus as CEPI vaccine coalition agreed to invest up to $54.3M to support a late-stage trial for the company's bird flu shot. Read more here.
Moderna Inc. will get as much as $54.3 million for a late-stage trial of its bird flu vaccine in a sign of how outside groups could help fill the void after the Trump administration slashed federal ...